It’s unlikely that will be disclosed, just as it wasn’t in the case of Optomed and AEYE Health.
Today’s news was welcome, but the 6% rise after the market open faded to less than half of that by the close. This is understandable, as the real sales work is only just beginning now, which has been the challenge so far.
However, there is still that algorithm developed with a big pharma company in the pipeline, the commercialization of which is currently being negotiated. Wasn’t it a top 10 company in the industry, or do I remember incorrectly? We could have heard something about the outcome of these negotiations by the end of last year, but so far we haven’t. I recall there was talk of the near future back then. So, this press release could also come out very soon, and if it really involves a big pharma company, I expect the stock price will get a much bigger boost than what we saw today.
I’m heading toward the Q4 earnings release with a positive mindset. If I recall correctly, a significant sum should be recognized as revenue in the software division for the final quarter. On the hardware side, we likely won’t see as massive percentage growth as in Q3 2025, because its comparison period was weak, and now the comparison period for Q4 2025 includes that large 1.5 million device order to the US from a year ago. Device sales in Q4 2024 were 2.6 million, and for comparison, Q3 2025 was 2.3 million. If we could reach even that 2.6 million comparison figure on the hardware side, it would be about 13% growth Q-on-Q. There could be even more growth if sales have been successful. For example, between Q2 and Q3 2025, the hardware segment saw good growth from 1.4 million to 2.3 million.
Much of that Q3 growth was traditional capex sales. The implementation of potential AI algorithms in the IQ cameras sold during said quarter, which Himberg previously mentioned, might not yet be visible in Q4. But we’ll know more in a month.